Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA extends digoxin elixir NDA deadline

Executive Summary

FDA extends deadline for companies to have an approved application for digoxin elixir from June 28 to Dec. 28. The extension was made because "it now appears that...there may not be any manufacturers prepared to market digoxin elixir under an approved application," a 1notice published in the June 29 Federal Register states. FDA set the original deadline in a final rule published June 28, 2002, which also required NDAs for digoxin tablets (2"The Pink Sheet" July 1, 2002, p. 12)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel